Abstract: Disclosed is an eye shield dispenser. The dispenser has a front panel, a rear panel, first and second front side panels, first and second rear side panels, a top panel, and a bottom panel. The front panel includes an access port providing access for removal of eye shields contained therein. An optional inclined surface is disposed in the interior of the dispenser near the access port, and eye shields are configured to be placed thereon and manually removed therefrom. The dispenser is shaped to generally correspond with the shape of the eye shields to hold the eye shields in place such that an inner insert is not required.

Abstract: The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (PAMPs).

Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.

Abstract: The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs).

Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.

Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.

Abstract: The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs).

Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.

Abstract: A novel granule dispersion composition which comprises water and, dispersed therein, a finely pulverized, sparingly water-soluble substance. The granule dispersion composition is prepared by dispersing in water a granular material which comprises a specific substance sparingly soluble in water, a polymer, and an oil and has an average particle diameter of 1 ?m or smaller and in which the ratio of the total weight of the polymer and oil to the weight of the specific substance is 1.5 or higher.

Abstract: A novel granule dispersion composition which comprises water and, dispersed therein, a finely pulverized, sparingly water-soluble substance. The granule dispersion composition is prepared by dispersing in water a granular material which comprises a specific substance sparingly soluble in water, a polymer, and an oil and has an average particle diameter of 1 ?m or smaller and in which the ratio of the total weight of the polymer and oil to the weight of the specific substance is 1.5 or higher.